Detalhe da pesquisa
1.
PPARγ partial agonist LPSF/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients.
Inflammopharmacology
; 32(1): 433-446, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37477795